Key Highlights

  • Relmada Therapeutics (NASDAQ:RLMD) rose 12.50% in after-hours trading at 5:47 PM Eastern on Thursday, November 12, 2026, following a bladder cancer data update.
  • The update concerns NDV-01, a treatment for a type of bladder cancer being tested in a mid-stage trial.
  • Among patients whose cancer was gone at one year, 14 reached the 18 month check, and 86% of them were still clear.
  • The sample is small, so the data supports continued development but does not yet establish how durable the effect is in a larger population.

What the Company Reported

Relmada Therapeutics (NASDAQ:RLMD) said that an analysis of patients treated with NDV-01 showed durable results in bladder cancer. Among patients whose disease had disappeared after one year, 14 had reached their 18 month assessment, and 86% of those patients remained free of cancer. That works out to 12 of 14 patients. The shares rose 12.50% in extended trading at 5:47 PM Eastern on Thursday. NDV-01 is being studied in a mid-stage trial for a form of bladder cancer, and the company's update focused on how long responses last, which is a central question for local therapies in this disease because recurrence is common. A strong early response is only valuable if it holds over time, so a high share of patients staying clear at 18 months is the type of signal that earns a company attention from investors and potential partners. The material reviewed did not give other durations, the enrolled total or the trial design in detail.

Why Small Numbers Need Caution

Fourteen patients is a small group, and 86% means that only two patients had a recurrence by the 18 month mark. A single additional recurrence would change the figure materially, so the Margin of error is wide. The patients are also a selected subset: those who were already clear at one year and then reached the 18 month assessment, which can show better results than the full treated population. Investors should look for the intent-to-treat figure, the response rate at the first assessment, safety and tolerability, and how results compare with existing options. Bladder cancer therapies are judged against a benchmark of durable complete response, and regulators look at the proportion of patients who remain clear for 12 months or more. Because trial updates from small companies often arrive when management wants to support financing or Partnership discussions, the stock reaction should be viewed alongside the potential for share sales after a rally.

What Happens Next

The next steps for Relmada Therapeutics (NASDAQ:RLMD) are a fuller presentation of the data, confirmation of how many patients were treated overall, and a timeline for later-stage development. Investors should track the regulatory path, including whether discussions with the FDA are planned, and the cash position needed to reach a registration study. After-hours moves of more than 10% in small biotechs are volatile and can narrow once regular trading opens on Friday, as Liquidity returns and holders choose whether to take profit. The broader market backdrop is not helpful: the S&P 500 fell 0.35% on Thursday and health care lost 0.59% as Treasury yields rose. Still, positive durability data is the kind of catalyst that can reset sentiment for a development stage company, provided that further enrollment confirms the early pattern. Investors should also ask whether the company intends to raise Capital after the move, since a quick Equity sale is a common response to a rally and would add shares to the count.

Where Things Stand

The company reported that 86% of 14 patients stayed clear at 18 months, and the shares rose 12.50% after hours. The key issues are sample size, selection and the plan for the next trial. Relmada Therapeutics (NASDAQ:RLMD) investors should wait for the full data set and Friday's regular session before judging how much of the move holds.